November TANOVEA®-CA1 Webinar Vlog – Anticipating and Addressing Adverse Effects

Posted on November 22nd, 2017 by Tom Schek

As part of a TANOVEA CA-1 Tuesdays webinar, Douglas H. Thamm, VMD, DACVIM (Oncology), presents information for veterinarians on possible adverse effects of treatment with the canine lymphoma drug, and explores strategies for anticipating and mitigating common gastrointestinal effects. This … Keep Reading

Cancer Treatment for Dogs and How Dogs Improve Our Health

Posted on November 9th, 2017 by Tom Schek

When your canine companion receives a lymphoma diagnosis, you naturally seek the latest cancer treatment for dogs (such as TANOVEA®-CA1 (rabacfosadine for injection)). But its not just owners who take care of dogs, dogs also take care of us. Studies have shown … Keep Reading

VetDC Announces New TANOVEA®-CA1 Publication, State of the Art Presentation at VCS 2017 Annual Conference

Posted on November 3rd, 2017 by Tom Schek

FORT COLLINS, Colo.–(BUSINESS WIRE)–VetDC, Inc., the leading veterinary cancer therapeutics company, today announced a new TANOVEA®-CA1 (rabacfosadine for injection) publication in Veterinary & Comparative Oncology. Data from this publication and several new VetDC-sponsored studies was prominently featured in a State … Keep Reading